A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
Jaume Capdevila(Vall d'Hebron Institut de Recerca), Alice Durand(Hôpital Edouard Herriot), Thomas Walter(Goethe University Frankfurt), David Taïeb(Aix-Marseille Université), Nicola Fazio(European Institute of Oncology), Sara Cingarlini, J.C. Ruffinelli(Institut Català d'Oncologia), Guillermo Villacampa(Hebron University), Côme Lepage(Inserm), Magalie Haissaguerre(Neurocentre Magendie), Jorge Hernando, Javier Molina‐Cerrillo(Hospital Universitario Ramón y Cajal), Francesco Panzuto(Sapienza University of Rome), Paula Jiménez‐Fonseca(Hospital Universitario Central de Asturias), Amparo García-Burillo, Rocio García‐Carbonero(Hospital Universitario 12 De Octubre), Sergio Baldari(University of Messina), Frank Aboubakar Nana(Cliniques Universitaires Saint-Luc), Maddalena Sansovini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Timon Vandamme(University of Antwerp), Virginia Pubul(Complejo Hospitalario Universitario de Santiago), Teresa Alonso‐Gordoa(Instituto Cajal), Urbano Anido(Universidade de Santiago de Compostela), Emmanuel Deshayes(Inserm), María San Román(Hospital Universitario 12 De Octubre), Angelina Filice(Azienda Sanitaria Unità Locale di Reggio Emilia), C. Ansquer(Centre Hospitalier Universitaire de Nantes), Marta Benavent Viñuales(Instituto de Biomedicina de Sevilla), Eric Baudin(Institut Gustave Roussy), Laurence Lousberg(Centre Hospitalier Chrétien), Amandine Béron(Centre Hospitalier Universitaire de Lille), Rosa Álvarez-Álvarez(Hospital General Universitario Gregorio Marañón), B. Fdez Llana(Hospital Universitario Central de Asturias), Alejandro García‐Álvarez
Cited by 7
Related Papers
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
|Neuroendocrinology|2017|495
Triple-negative breast cancer: treatment challenges and solutions
|Breast Cancer Targets and Therapy|2016|382
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
|The Lancet|2023|319
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271